Mantle Cell Lymphoma Trials

ENRICH

Description:
Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma

Phase:
integrated phase II/III

Start:
22/12/2015

End:
31/12/2022

7.5 years

Locations:
Plymouth Hospitals NHS Trust

Treatments:
Intervention arm: 126 weeks (2.5 years) of IR however ibrutinib continues until disease progression or end of study.

Control arm: 126 weeks (2.5 years)

Objectives:
Primary
Progression Free Survival at 30 months post-randomisation

Secondary
Overall survival, Disease response, Minimal residual disease using flow cytometry tests, Safety and toxicity, Quality of life (EORTC QLQ-30), Cost of delivery, Time to next treatment

Funder
Cancer Research UK

Enrollment Criteria:

Health Professionals requiring information on trials and access to our professional section of the website can register here

« Back to list of trials

Plymouth Hospitals NHS Trust UKCRC Plymouth University Peninsula

Beechwood Communications Web Design  Web Design by Beechwood